Keynote
Opening Keynote Session
Sun, Sep 28, 2025 · 9:30–11:00 AM EDT Ballroom I-II, Baltimore Convention Center
About this session
After advising world leaders, royal households, and Fortune 500 companies, Matthew Griffin is coming to the SCDM stage to examine how emerging technologies, already deployed in regulatory and biopharma settings, are redefining data workflows, trial design, and decision-making.
At SCDM 2025, he’ll walk us through:
- How AI, IoT, and synthetic data are transforming clinical trials and data collection
- Real-world examples of FDA and U.S. programmes using AI to develop and approve drugs
- The rise of digital humans and chip-based trials, and what that means for data integrity and validation
The automation of the clinical trial lifecycle, from protocol design to regulatory approval
